The Swedish pharmaceutical company, AlzeCure Pharma AB, focuses on drug research for Alzheimer's disease and pain, developing five drug candidates within its two research platforms: NeuroRestore and Alzstatin. The NeuroRestore platform targets symptom relief, while Alzstatin aims to modify and prevent the disease. The company's diversified portfolio of drug candidates also has potential for treating other indications, such as cognitive dysfunctions in traumatic brain injury and Parkinson's disease. Additionally, the company has a preclinical phase project for pain, TrkA-NAM. AlzeCure Pharma AB is listed on the Nasdaq First North Premier Growth Market and is advised by FNCA Sweden AB.